TITLE
Phase I/Ii study of mTOR inhibitor everolimus and Hyper-CVAD plus RAD001 (Everolimus) chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

ORGANISM
Homo sapiens

SUMMARY
Analysis of the effects of everolimus on gene expression and if this correlates to drug and/or clinical response.

DESIGN
RNA exracted from peripheral blood before and 24 hours after treatment with everolimus.

PLATFORM
GPL10558 Illumina HumanHT-12 V4.0 expression beadchip

CITATIONS
Has this study been published? Please login to update or notify GEO .

